Document is current

Article History

First Online: 7 March 2020

Compliance with Ethical Standards

:

: Joseph S. Dillon: Lexicon Pharmaceuticals, Inc. (RF); Matthew H. Kulke: Lexicon Pharmaceuticals, Inc. (C/A), Ipsen Bioscience (C/A), Novartis Pharmaceuticals (C/A); Dieter Hörsch: Lexicon Pharmaceuticals, Inc. (H), Ipsen Pharmaceuticals, Inc. (RF, H); Lowell B. Anthony: Lexicon Pharmaceuticals, Inc. (RF, H); Richard R. P. Warner: Lexicon Pharmaceuticals, Inc. (RF); Emily Bergsland: UpToDate (IP), Novartis (RF); Staffan Welin: Ipsen (C/A), Novartis (C/A); Pamela L. Kunz: Lexicon Pharmaceuticals, Inc. (C/A), Advanced Accelerator Applications (RF), Genentech (RF), Ipsen (RF), Merck (RF), Incyte (RF); Chad McKee: Lexicon Pharmaceuticals, Inc. (E, OI); Pablo Lapuerta: Lexicon Pharmaceuticals, Inc. (E, OI); Phillip Banks: Lexicon Pharmaceuticals, Inc. (E, OI); Marianne Pavel: Novartis Pharmaceuticals (RF, H), Ipsen (RF, H), Lexicon Pharmaceuticals, Inc. (H), Pfizer, Inc. (H). Thomas M. O’Dorisio indicated no financial relationships.(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

: Informed consent was obtained from all individual participants included in the study.